Omnicell (OMCL) Tops Q4 EPS by 24c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Omnicell Announces Fiscal Year and Fourth Quarter 2022 Results
February 28, 2023 4:01 PM EST2022 Total Bookings of $1.054 billion
Full Year 2022 GAAP Revenues of $1.296 and non-GAAP Revenues of $1.297 billion
Ended Year with Over 150 Long-Term, Sole-Source Agreements with the Top 300 U.S. Health Systems
Year End 2022 Backlog of $1.215 billion
Chief Financial Officer to Step Down effective July 1, 2023
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL) (Omnicell, we, our, us, management, or the Company), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results... More
